Galapagos NV (GLPGF)
USD 22.39
(0.0%)
USD 22.39
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.59 Million EUR | -56.18% |
| 2022 | 21.9 Million EUR | -18.46% |
| 2021 | 26.85 Million EUR | -8.75% |
| 2020 | 29.43 Million EUR | 15.96% |
| 2019 | 25.38 Million EUR | 0.0% |
| 2018 | - EUR | -100.0% |
| 2017 | 9000.00 EUR | -85.71% |
| 2016 | 63 Thousand EUR | -45.22% |
| 2015 | 115 Thousand EUR | -31.14% |
| 2014 | 167 Thousand EUR | -57.51% |
| 2013 | 393 Thousand EUR | -2.96% |
| 2012 | 405 Thousand EUR | -53.77% |
| 2011 | 876 Thousand EUR | -29.64% |
| 2010 | 1.24 Million EUR | -16.11% |
| 2009 | 1.48 Million EUR | -12.81% |
| 2008 | 1.7 Million EUR | -61.03% |
| 2007 | 4.36 Million EUR | -43.76% |
| 2006 | 7.76 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.97 Million EUR | -16.87% |
| 2024 Q2 | 10.87 Million EUR | 36.3% |
| 2023 Q2 | 15.41 Million EUR | -3.65% |
| 2023 Q4 | 9.59 Million EUR | -32.17% |
| 2023 Q1 | 15.99 Million EUR | -26.95% |
| 2023 Q3 | 14.14 Million EUR | -8.23% |
| 2023 FY | 9.59 Million EUR | -56.18% |
| 2022 Q4 | 21.9 Million EUR | -3.46% |
| 2022 FY | 21.9 Million EUR | -18.46% |
| 2022 Q1 | 25.35 Million EUR | -5.6% |
| 2022 Q2 | 24.05 Million EUR | -5.13% |
| 2022 Q3 | 22.68 Million EUR | -5.69% |
| 2021 Q3 | 26.39 Million EUR | -5.44% |
| 2021 FY | 26.85 Million EUR | -8.75% |
| 2021 Q4 | 26.85 Million EUR | 1.78% |
| 2021 Q2 | 27.9 Million EUR | -2.59% |
| 2021 Q1 | 28.65 Million EUR | -2.67% |
| 2020 FY | 29.43 Million EUR | 15.96% |
| 2020 Q1 | 25.06 Million EUR | -1.25% |
| 2020 Q2 | 27.25 Million EUR | 8.74% |
| 2020 Q3 | 29.06 Million EUR | 6.64% |
| 2020 Q4 | 29.43 Million EUR | 1.27% |
| 2019 Q2 | 25.59 Million EUR | 2.44% |
| 2019 Q3 | 24.91 Million EUR | -2.68% |
| 2019 Q4 | 25.38 Million EUR | 1.89% |
| 2019 FY | 25.38 Million EUR | 0.0% |
| 2019 Q1 | 24.98 Million EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 FY | - EUR | -100.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 9000.00 EUR | 0.0% |
| 2017 FY | 9000.00 EUR | -85.71% |
| 2017 Q1 | 50 Thousand EUR | -20.63% |
| 2017 Q2 | 37 Thousand EUR | -26.0% |
| 2016 Q3 | 76 Thousand EUR | -15.56% |
| 2016 FY | 63 Thousand EUR | -45.22% |
| 2016 Q4 | 63 Thousand EUR | -17.11% |
| 2016 Q2 | 90 Thousand EUR | -11.76% |
| 2016 Q1 | 102 Thousand EUR | -11.3% |
| 2015 Q4 | 115 Thousand EUR | -9.45% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 115 Thousand EUR | -31.14% |
| 2015 Q2 | 140 Thousand EUR | 0.0% |
| 2015 Q3 | 127 Thousand EUR | -9.29% |
| 2014 Q4 | 167 Thousand EUR | 0.0% |
| 2014 FY | 167 Thousand EUR | -57.51% |
| 2014 Q1 | 140 Thousand EUR | -64.38% |
| 2014 Q2 | 254 Thousand EUR | 81.43% |
| 2013 Q3 | 167 Thousand EUR | -68.37% |
| 2013 FY | 393 Thousand EUR | -2.96% |
| 2013 Q2 | 528 Thousand EUR | 87.23% |
| 2013 Q1 | 282 Thousand EUR | -30.37% |
| 2013 Q4 | 393 Thousand EUR | 135.33% |
| 2012 Q4 | 405 Thousand EUR | 0.0% |
| 2012 FY | 405 Thousand EUR | -53.77% |
| 2012 Q2 | 679 Thousand EUR | 0.0% |
| 2011 Q4 | 876 Thousand EUR | 0.0% |
| 2011 Q2 | 1.16 Million EUR | 0.0% |
| 2011 FY | 876 Thousand EUR | -29.64% |
| 2010 Q4 | 1.24 Million EUR | 0.0% |
| 2010 Q2 | 1.27 Million EUR | 0.0% |
| 2010 FY | 1.24 Million EUR | -16.11% |
| 2009 Q2 | 1.75 Million EUR | 0.0% |
| 2009 FY | 1.48 Million EUR | -12.81% |
| 2009 Q4 | 1.48 Million EUR | 0.0% |
| 2008 Q4 | 1.7 Million EUR | 0.0% |
| 2008 FY | 1.7 Million EUR | -61.03% |
| 2007 FY | 4.36 Million EUR | -43.76% |
| 2006 FY | 7.76 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 52.794% |
| Skye Bioscience, Inc. | 4.61 Million USD | -107.919% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 67.763% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -7733.469% |
| Qrons Inc. | 351.84 Thousand USD | -2627.322% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -103.675% |
| CSL Limited | 12.18 Billion USD | 99.921% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 77.876% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -63.445% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1168.97% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 78.938% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2995.484% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1422.988% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -37210.937% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 76.71% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -132.802% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2287.962% |
| SQZ Biotechnologies Company | 27.47 Million USD | 65.069% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -312.562% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -911.947% |
| Mesoblast Limited | 118.7 Million USD | 91.916% |
| Marizyme, Inc. | 18.71 Million USD | 48.732% |
| Genus plc | 233.1 Million USD | 95.883% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -227.465% |
| Pharming Group N.V. | 171.54 Million USD | 94.406% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -980.553% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -614.209% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1179.467% |
| ContraFect Corporation | 2.88 Million USD | -233.079% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6982.598% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -563.477% |
| IMV Inc. | 28.88 Million USD | 66.777% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -69.59% |
| MultiCell Technologies, Inc. | 202.58 USD | -4736794.067% |
| ONE Bio Corp. | 19.71 Million USD | 51.326% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 83.308% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -541.98% |
| Q BioMed Inc. | 4.1 Million USD | -133.48% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 71.01% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -681.204% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1204.616% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 85.814% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -217.098% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 26.168% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2567.705% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -6680.763% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -324.906% |
| GB Sciences, Inc. | 1.75 Million USD | -445.442% |
| Alpha Cognition Inc. | 1.22 Million USD | -686.318% |
| HST Global, Inc. | 98.31 Thousand USD | -9660.067% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3758.154% |
| Halberd Corporation | 150 Thousand USD | -6297.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -863.127% |
| Agentix Corp. | 50 Thousand USD | -19092.0% |
| Resverlogix Corp. | 6.49 Million USD | -47.835% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3654.421% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 52.02% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -35.675% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -254.265% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -93748.411% |
| Genscript Biotech Corporation | 417.73 Million USD | 97.703% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4683.268% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -300.213% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -4085.075% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -6355.259% |
| Kadimastem Ltd | 891.22 Thousand USD | -976.719% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3735.608% |
| LadRx Corporation | 33.6 Thousand USD | -28454.425% |
| Cell Source, Inc. | 9.25 Million USD | -3.694% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1168.97% |
| NovAccess Global Inc. | 2.19 Million USD | -336.206% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -4101.824% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -4448.406% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -92.575% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1881.482% |
| CytoDyn Inc. | 30.07 Million USD | 68.094% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -22.712% |
| SYBLEU INC | 477.5 Thousand USD | -1909.634% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -102.649% |
| International Stem Cell Corporation | 4.17 Million USD | -129.679% |
| Bioxytran, Inc. | 1.92 Million USD | -398.494% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -15275.002% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -340.002% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -15.392% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -11.776% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -516.916% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -3480.597% |
| Neutra Corp. | 54.15 Thousand USD | -17619.182% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -424.372% |
| PureTech Health plc | 25.51 Million USD | 62.386% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -683.842% |
| IXICO plc | 472.02 Thousand USD | -1932.952% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 38.094% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 84.588% |
| CSL Limited | 12.18 Billion USD | 99.921% |
| Cellectis S.A. | 92.77 Million USD | 89.657% |